May Measurement Month 2017: an analysis of blood pressure screening in Hungary—Europe by Nemcsik, János et al.
May Measurement Month 2017: an analysis of blood
pressure screening in Hungary—Europe
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1Hungarian Society of Hypertension, 12-16 Tétényi str., Budapest, 1115, Hungary;
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3Health Service of Zugló (ZESZ), 23 Örs vezér place, Budapest, 1148, Hungary;
4Department of Medicine and Coordination Centre for Drug Development, University of Debrecen, 98 Nagyerdei bou-
levard, Debrecen, 4012, Hungary;
51st Department of Internal Medicine, Medical School, University of Szeged, 8-10 Korányi alley, Szeged, 6720, Hungary;
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Elevated blood pressure (BP) is a growing burden worldwide, leading to over 10 million deaths each year. The cardiovascu-
lar mortality rate in Hungary is twice as high as the European Union average. In a recent Hungarian screening programme,
among those volunteers who claimed to be healthy, BP was above 140/90mmHg in 24% and 39% in women and men, while
the control rate was 45% and 36% in women and men, respectively. May Measurement Month (MMM) is a global initiative
by the International Society of Hypertension aimed at raising awareness of high BP and to act as a temporary solution to
the lack of screening programmes worldwide. An opportunistic cross-sectional survey of volunteers aged 18 was carried
out in May 2017. BP measurement, the definition of hypertension and statistical analysis followed the standard MMM pro-
tocol. In Hungary, 97 sites were set-up in primary and secondary care facilities, in pharmacies and in malls. All regions,
both cities and villages were involved. A total of 3967 individuals were screened. After multiple imputation, 2052 subjects
(51.8%) had hypertension. 553 (22.4%) of untreated individuals had hypertension, and 666 (44.5%) of treated individuals
had uncontrolled BP. More than 50% of the screened cohort had hypertension (treated and controlled, treated and uncon-
trolled or untreated). By identifying almost one-third of the screened cohort with the possibility of newly diagnosed or
uncontrolled hypertension, the Hungarian part of MMM17 suggest that opportunistic screening can identify significant
numbers with raised BP.
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Background
Hypertension is the leading cause of mortality and
disability-adjusted life years all over the world.1 In the
USA, hypertension is at the top of the list among single risk
factors accounting for cardiovascular disease (CVD) deaths
and was second after smoking as a preventable cause of
death for any reason.2
In Hungary, CVD mortality is an enormous public health
problem. Among women 55%, while among men 45% of
deaths were attributed to CVD in 2013.3 Between 2000 and
2012 CVD mortality decreased by about 30% in both sexes
and in both age categories of 40–59 years and 60–79 years.
This was due to a reduction in a combination of ischaemic
heart disease and stroke.4 However, compared with other
European Union countries Hungary is still in a bad position.
In 2014, Hungary with Lithuania, Latvia, and Slovakia had
one of the four highest rates of ischaemic heart disease
mortality with 487/100 000 deaths/year in men and 327/
100 000 deaths/year in women. In respect of cerebrovascu-
lar mortality Hungary is also in the worst quartile of the
European Union countries with 174/100 000 deaths/year in
men and 130/100 000 deaths/year in women.5
The prevention and adequate therapy of hypertension,
as a major contributor to CVD mortality, has utmost impor-
tance to further improve the still poor statistics of
Hungary. Based on the coding of hypertension in general
practitioner practices, the number of diagnosed hyperten-
sive patients in Hungary has grown from 2.5 million in 1999
to more than 3.5 million in 2015.6 The Hungarian Society of
Hypertension funded a national hypertension registry in
2002. Based on the recent data of 27 399 consecutive hy-
pertensive patients evaluated in 2015, 44.9% of the
patients reached the target of 140/90mmHg, but only 9.6%
had values under 130/80mmHg.7 So every campaign that
aims at increasing hypertension awareness in our country
has exceptional importance. That is why the Hungarian
Society of Hypertension decided to join MMM 2017
(MMM17), the hypertension awareness campaign of the
International Society of Hypertension (ISH). Hereafter, we
provide the Hungarian data of MMM17.
Methods
This was a cross-sectional survey planned and distributed
worldwide by the ISH. The Hungarian co-ordinator was
Professor István Kiss, at that time the president of the
Hungarian Society of Hypertension, who tragically died in
May 2018.
Prior to participation, all patients gave written informed
consent. The study was approved by the Scientific and
Research Ethical Committee of the Medical Research
Council, the Hungarian Ministry of Health (ETT TUKEB
25151-2/2017/EKU) and was carried out in accordance
with the tenets of the Declaration of Helsinki.
The survey was carried out following the instructions of
ISH.8 Sites were set-up in primary and secondary care facil-
ities, in pharmacies and occasionally in shopping malls.
Target subjects were adult volunteers (18years), who
had not had their blood pressure (BP) measured in the
previous year. Site leader physicians and assistants were
recruited and trained by the Hungarian Society of
Hypertension. The campaign was promoted by scientific
newsletters of the society and through the social media.
Recommendation for standard methods included the
measurement of arm circumference for appropriate cuff
size use; left side measurement preferably; at least 5min
resting before measurements in seated position; prohibi-
tion of smoking before and during the measurement; three
consecutive measurements 1min apart and the use of pref-
erably validated automated oscillometric upper-arm cuff
devices (device type not registered). The mean of the 2nd
and the 3rd BP measurement was calculated. Hypertension
was defined as a systolic BP 140mmHg or diastolic BP
90mmHg or taking anti-hypertensivemedication.
Screening took place between the 1 and 31 May 2017 and
data were collected via scanned or mailed paper sheets.
Altogether 97 sites were involved and data were col-
lected by the headquarters of the Hungarian Society of
Hypertension and without local cleaning were directly
transferred to ISH. State data were analysed centrally by
the MMM/ISH project team.8 There were no sources of
funding.
Results
A total of 3967 Caucasian subjects participated (mean age
50.2, SD 16.8years). As data collection was incomplete for
some of the variables in the study questionnaire, numbers
vary in different analyses.
Women were represented in higher proportion than men
(n¼ 2365, 59.6% and n¼ 1602, 40.4%, respectively). Mean
BMI was 26.7kg/m2, 1110 (28%) subjects were current
smokers and 255 (6.4%) reported consumption of alcohol
once or more per week. A total of 1499 subjects (37.8%)
were on anti-hypertensive medication, 548 (13.8%) had di-
abetes, 502 (12.7%) had a history of myocardial infarction
and 180 (4.5%) a history of stroke. Most of the BP measure-
ments were performed on the left arm (82.2%).
In the whole cohort the mean BP was 129.4/79.9mmHg.
After imputation and standardizing for age and gender, in
those patients who did not receive anti-hypertensive medi-
cation, the mean BP was 125.7/78.6mmHg, while in
treated subjects 134.5/82.7mmHg. The proportion of
untreated normotensive subjects was 48% (n¼ 1912). The
proportion of subjects not on treatment who were found to
have high BP was 22.4% (n¼ 553). On the other hand, the
proportion of treated patients with uncontrolled BP was
44.5% (n¼ 666).
After adjustment for age and sex, significantly higher
systolic and diastolic BPs were found in subjects receiving
anti-hypertensivemedication (see Supplementary material
online, Figure S1). After adjustment for age, sex, and anti-
hypertensive medication systolic and diastolic BP was
higher in patients who regularly take alcohol, while only
systolic was higher in those with diabetes and in smokers.
Increasing BMI was also associated with the elevation of
both systolic and diastolic BPs (see Supplementary material
online, Figure S2).
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Discussion
As part of MMM17, the largest synchronized, standardized
multinational screening campaign of any cardiovascular
risk factor ever to be done all over the world, Hungary was
represented with 3967 subjects involved. More than half of
the whole cohort had hypertension (treated or untreated).
The proportion of subjects with uncontrolled hypertension
was 22.4% among untreated patients and twice as high
(44.5%) among treated patients.
By identifying 1219 subjects with the possibility of newly
diagnosed or uncontrolled hypertension, which was 30.7% of
the whole screened cohort, the Hungarian part of MMM17
once again demonstrated the important role of screening
hypertension for primary and secondary prevention, as well.
Besides the direct benefit for the identified undiagnosed hy-
pertensive patients, these data also can provide ammuni-
tion for the fight for stronger support of hypertension care
at a governmental level. With an inexpensive and simple
screening method such as this, followed by the proper inter-
vention, many CVD events and deaths can be avoided.
In Hungary, since 2010 a unique national CVD screening
programme has been ongoing. A specially furnished lorry is
moving throughout the country, in which different exami-
nations are carried out. Until the end of 2017, the screen-
ing truck had been to 1505 places, 135 879 people had
participated in comprehensive screening and 124 557 peo-
ple had relevant BP measurement, with 11 601 successful
measurements in 2017.9 In 2017, among those patients who
were self-reported as healthy, BP was above 140/90mmHg
in 24.2% and 39.2% of women and men, respectively. In
those with a history of hypertension it was uncontrolled in
55.2% and 63.8% in women and men, respectively. We as-
sume that the comparison of these results or the results of
the Hungarian Hypertension Registry with the Hungarian
MMM17 findings is inappropriate because of the divergent
screening sites of MMM17, but it is obvious, that a huge pro-
portion of the screened people in MMM17 was found to be
in the high BP range.
In conclusion, the results of MMM17 in Hungary highlight
the importance and value of hypertension screening at a
population level. Such campaigns can increase the aware-
ness of hypertension which can lead to the reduction of
CVD complications.
Supplementary material
Supplementary material is available at European Heart
Journal - Supplements online.
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